BioCryst Pharmaceuticals (NASDAQ:BCRX) reported strong first-quarter results, surpassing expectations thanks to the success of its FDA-approved drug, ORLADEYO. This drug has the potential to reach $1 billion in peak sales. Despite a recent 20% increase in the stock price, BCRX shares are still undervalued, indicating room for further growth. For value-oriented investors interested in biopharma with growth potential, BioCryst presents an attractive opportunity.
BioCryst is focused on developing treatments for complement-mediated and rare diseases. ORLADEYO, the company’s first oral, once-daily plasma kallikrein inhibitor, has shown commercial success with increasing revenues. The drug is gaining traction both in the U.S. and internationally. Additionally, BioCryst has a pipeline of rare disease products, including BCX10013 and BCX17725, which are progressing well in trials.
Financially, BioCryst exceeded expectations in Q1 2024, with revenue of $92.8 million and earnings per share of -$0.17. The company’s cash and investments stand at $338.4 million, with projected revenue and expenses for the rest of 2024 aligning with growth expectations. Analysts have raised price targets for BCRX stock, with a strong buy rating and an average price target of $15.33, representing a significant upside potential.
Overall, BioCryst Pharmaceuticals shows promise with its successful drug and pipeline of clinical candidates. With undervalued shares and positive momentum, the company is an attractive option for investors looking for growth in the biopharma sector.